Skip to main content

CORRECTION article

Front. Pharmacol., 15 July 2021
Sec. Pharmacology of Anti-Cancer Drugs

Corrigendum: PKM2-Induced the Phosphorylation of Histone H3 Contributes to EGF-Mediated PD-L1 Transcription in HCC

Xiao WangXiao Wang1Chao LiangChao Liang1Xin YaoXin Yao1Ruo-Han YangRuo-Han Yang1Zhan-Sheng ZhangZhan-Sheng Zhang1Fan-Ye LiuFan-Ye Liu1Wen-Qi LiWen-Qi Li1Shu-Hua PeiShu-Hua Pei1Jing Ma
Jing Ma1*Song-Qiang Xie,
Song-Qiang Xie1,2*Dong Fang
Dong Fang1*
  • 1Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China
  • 2Institute of Chemical Biology, School of Pharmacy, Henan University, Kaifeng, China

A corrigendum on

PKM2-Induced the Phosphorylation of Histone H3 Contributes to EGF-Mediated PD-L1 Transcription in HCC

by Wang, X., Liang, C., Yao, X., Yang, R.-H.., Zhang, Z.-S.., Liu, F.-Y., Li, W.-Q., Pei, S.-H., Ma, J., Xie, S.-Q., and Fang, D. (2020). Front. Pharmacol. doi: 10.3389/fphar.2020.577108

In the original article, there were several errors in “Figures and Figure legends.”

In Figure 2 as published, the letters B and C which indicated the figure order were marked in reverse. In Figure 4, the letters from B to E which indicated the figure order were marked in reverse, and the figure label “EGF” was missed in the second and third bands in western blots in Figure 4B. In Figure 6B, the figure label “EGFR” was marked as “β-actin” mistakenly. Besides, we mistakenly wrote PD-L1 as DKK1 in Figure legends 2, 4, and 6 because of our carelessness. The corrected Figures 2, 4 and 6 appear below.

FIGURE 2
www.frontiersin.org

FIGURE 2. EGFR activation is required for PD-L1 expression in SNU-368 cells. (A,B) Knockdown of EGFR with specific shRNA reversed EGF-induced PD-L1 mRNA (A) and protein (B) expressions in SNU-368 cells. At 24 h post-transfection, the cells were incubated in the presence or absence of 100 ng/ml EGF for 12 h. **p < 0.01, ***p < 0.001, one-way ANOVA, n = 4 independent experiments per group. (C,D) EGF-induced upregulation of PD-L1 mRNA (C) and protein (D) was blocked by gefitinib. ***p < 0.001, one-way ANOVA, n = 5 independent experiments per group.

FIGURE 4
www.frontiersin.org

FIGURE 4. Phosphorylation of PKM2 at Ser37 participates in EGF‐induced PD‐L1 expression. (A,B) PKM2 shRNA blocked EGF‐induced PD‐L1 mRNA (A) and protein (B) expressions in SNU‐368 cells. At 24 h post‐transfection, the cells were incubated in the presence or absence of 100 ng/ml EGF for 12 h. **p < 0.01, ***p < 0.001, one‐way ANOVA, n = 4 independent experiments per group. (C,D) The expression of a phosphorylation‐mimic PKM2 S37D mutant induced a higher expression of PD‐L1 mRNA (C) and protein (D) compared with WT PKM2 or the S37A mutant in SNU‐368 cells. **p < 0.01, one-way ANOVA, n = 4 independent experiments per group. (E) ChIP analyses showed that the expression of a phosphorylation‐mimic PKM2 S37D mutant resulted in increased binding of PKM2 to PD‐L1 promoter in SNU-368 cells. *p < 0.05, **p < 0.01, one-way ANOVA, n = 5 independent experiments per group.

FIGURE 6
www.frontiersin.org

FIGURE 6. DEN treatment induced a significant upregulation of phospho-EGFR, phospho-H3, and PKM2 nuclear accumulation in rat livers. (A) Top, representative photos of livers from normal and DEN-treated rats; bottom, representative images of H&E-stained livers. (B) The phosphorylational level of EGFR at Tyr1068 was increased in the livers of DEN-treated rats. **p < 0.01, two-tailed unpaired t-test, n = 8 rats per group. (C) The expression of PKM2 nuclear protein was upregulated in the livers of DEN-treated rats. Lamin B1 was used as an internal control, and β-actin was used as a negative control. **p < 0.01, two-tailed unpaired t-test, n = 8 rats per group. (D) The phosphorylational level of H3-Thr11 was increased in the livers of DEN-treated rats. **p < 0.01, two-tailed unpaired t-test, n = 8 rats per group. (E,F) The expression of PD-L1 mRNA (E) and protein (F) was increased in the livers of DEN-treated rats. **p < 0.01, ***p < 0.001, two-tailed unpaired t-test, n = 8 rats per group. (G) ChIP analyses showed that DEN administration resulted in enhanced H3-Thr11 phosphorylation at the PD-L1 promoter in rats. **p < 0.01, two-tailed unpaired t-test, n = 8 rats per group.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: epidermal growth factor, pyruvate kinase isoform M2, histone H3, programmed death-ligand-1, hepatocellular carcinoma

Citation: Wang X, Liang C, Yao X, Yang R-H, Zhang Z-S, Liu F-Y, Li W-Q, Pei S-H, Ma J, Xie S-Q and Fang D (2021) Corrigendum: PKM2-Induced the Phosphorylation of Histone H3 Contributes to EGF-Mediated PD-L1 Transcription in HCC. Front. Pharmacol. 12:724799. doi: 10.3389/fphar.2021.724799

Received: 14 June 2021; Accepted: 22 June 2021;
Published: 15 July 2021.

Edited and Reviewed by:

William Valentine Williams, BriaCell Therapeutics Corp., United States

Copyright © 2021 Wang, Liang, Yao, Yang, Zhang, Liu, Li, Pei, Ma, Xie and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jing Ma, majing.1988.ok@163.com; Song-Qiang Xie, xiesq@henu.edu.cn; Dong Fang, emailfangdong@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.